2026-01-02 - Analysis Report
Okay, let's break down this Recursion Pharmaceuticals Inc (RXRX) analysis step-by-step.

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging technology to discover, develop, and deliver medicines.

## 1) Return Rate Comparison

*   **RXRX Cumulative Return:** -33.76%
*   **VOO (S&P 500) Cumulative Return:** 43.29%
*   **Divergence:** -77.0 (Relative Divergence: 0.7)

**Analysis:** RXRX has significantly underperformed the S&P 500 (VOO). The cumulative return is deeply negative, while the S&P 500 has shown a strong positive return. The divergence of -77.0 indicates a substantial gap between the stock's performance and the market benchmark. The relative divergence of 0.7, close to the minimum of 0, suggests the stock is currently near the lower end of its historical divergence range compared to VOO.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha   | Beta | Cap(B) |
|------------|----------|----------|---------|------|--------|
| 2022-2024  | -43.0%   | 82.1%    | -73.0%  | 2.3  | 3.5    |
| 2023-2025  | -51.0%   | 88.8%    | -119.0% | 2.6  | 2.1    |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  The CAGR is deeply negative for both periods, highlighting the significant losses incurred by the stock.
*   **MDD (Maximum Drawdown):** The MDD is very high (over 80%), indicating substantial risk and large potential losses from peak to trough.
*   **Alpha:**  Alpha is strongly negative, meaning the stock has significantly underperformed its benchmark on a risk-adjusted basis.  This reinforces the underperformance relative to the S&P 500.
*   **Beta:** Beta is greater than 1, suggesting that RXRX is more volatile than the overall market. A Beta around 2 implies that RXRX experiences approximately twice the volatility of the S&P 500.
*   **Cap(B):** The market capitalization has decreased from 3.5B to 2.1B.

## 2) Recent Stock Price Fluctuations

*   **Current Close:** 4.09
*   **Previous Close:** 4.11
*   **Change:** -0.49%
*   **5-day SMA:** 4.196
*   **20-day SMA:** 4.454
*   **60-day SMA:** 4.9225

**Analysis:** The stock price has been declining recently. The current price is below all three moving averages, indicating a short-term and medium-term downtrend. The 5-day SMA is below the 20-day SMA, which is below the 60-day SMA, confirming the downward trend.

## 3) Index Indicators

*   **Market Risk Indicator (MRI):** 0.9 (Medium Investment)
*   **RSI:** 33.00
*   **PPO:** -0.5268
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (228 shares - Very Safe - MRI:0.90) Monthly invest 1.7% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 0.7 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** 0.0%

**Analysis:**

*   **MRI (0.9):** Indicates a medium level of investment risk based on this indicator.
*   **RSI (33.00):**  The RSI is below 30, suggesting the stock may be oversold and potentially poised for a rebound.
*   **PPO (-0.5268):** The PPO is negative, indicating a downtrend.
*   **Hybrid Signal:** Despite the negative indicators, the hybrid signal suggests a "Buy" recommendation, allocating all available cash to purchasing shares. This is based on the safety indicated by the MRI.
*   **Recent Relative Divergence Change:** A positive change in relative divergence suggests the stock has recently started to outperform (or decline less than) its benchmark.
*   **Expected Return:** The expected return is 0%, indicating no expected outperformance relative to the S&P 500 in the long term (2+ years).

## 4) Recent News & Significant Events

*   **[2025-12-29] RXRX Stock Plummet:** Indicates negative price action.
*   **[2026-01-01] Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy:** Suggests analysts believe there are better investment opportunities elsewhere.
*   **[2025-12-13] $RXRX stock fell 9% this week:** Confirms recent price declines.
*   **[2025-12-18] RXRX Stock Surges on JPMorgan Upgrade, Trial Data Gains:** Positive news that caused a temporary price increase.
*   **[2026-01-01] Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy:** Repeated negative sentiment.
*   **[2025-12-24] Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition:** This suggests that analysts are re-evaluating the company based on specific trial data, potential institutional buying, and upcoming leadership changes.

**Analysis:** Recent news is mixed. While there was a surge on a JPMorgan upgrade and positive trial data, the prevailing sentiment seems cautious, with some outlets suggesting better investment alternatives. The news highlights the volatility and uncertainty surrounding the stock.

## 4-2) Analyst Opinions

*   **Analyst Consensus:**
    *   Key: None
    *   Mean (1=StrongBuy~5=Sell): - (~-)
    *   Opinions: 7
    *   Target Price (avg/high/low): 7.00 / 11.00 / 3.00
    *   Recent Rating Changes:  No significant rating changes reported

**Analysis:** Analyst ratings are neutral (no specific recommendation), but the target price range is wide (3.00 to 11.00), reflecting uncertainty about the company's future prospects. The average target price of 7.00 suggests a significant upside from the current price, but the low target price of 3.00 indicates that some analysts are bearish.

## 5) Recent Earnings Analysis

| 날짜       | EPS   | 매출     |
|------------|-------|----------|
| 2025-11-05 | -0.36 | 0.01 B$  |
| 2025-08-05 | -0.41 | 0.02 B$  |
| 2025-05-05 | -0.50 | 0.01 B$  |
| 2024-11-06 | -0.34 | 0.03 B$  |
| 2025-11-05 | -0.34 | 0.03 B$  |

**Analysis:** RXRX has consistently reported negative EPS (Earnings Per Share), indicating losses. Revenue has fluctuated between $0.01B and $0.03B. There is no clear trend of improvement in either EPS or revenue.

## 6) Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-09-30 | $0.00B  | -194.74%      |
| 2025-06-30 | $0.02B  | -5.54%        |
| 2025-03-31 | $0.01B  | -47.31%       |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2025-09-30 | $1.05B    | -15.50%  |
| 2025-06-30 | $0.92B    | -18.70%  |
| 2025-03-31 | $0.93B    | -21.68%  |
| 2024-12-31 | $1.03B    | -17.29%  |
| 2024-09-30 | $0.52B    | -18.27%  |

**Analysis:** Revenue is generally low and inconsistent. Profit margins are mostly negative, often significantly so, indicating the company is spending substantially more than it earns. Equity has fluctuated, and Return on Equity (ROE) is consistently negative, reflecting the company's inability to generate profits from shareholders' investments. The spike in revenue in Q3 2024 did result in a temporary positive Profit Margin, but this has not been sustained.

## 7) Comprehensive Analysis (Summary)

Recursion Pharmaceuticals (RXRX) is a high-risk investment. Here's a summary of the key takeaways:

*   **Underperformance:** RXRX has significantly underperformed the S&P 500.
*   **Volatility:** The stock is more volatile than the market.
*   **Financials:** The company is consistently unprofitable, with low and fluctuating revenues and negative profit margins and ROE.
*   **Sentiment:** Recent news is mixed. While there are some positive developments (JPMorgan upgrade, trial data), overall sentiment seems cautious, and some analysts suggest better investment options.
*   **Technical Indicators:** The stock is in a short-term downtrend, with the price below key moving averages.  The RSI suggests it might be oversold, but this alone is not a reason to buy.
*   **Analyst Opinions:** Analysts have a wide target price range, reflecting uncertainty.
*   **MRI Signal:** Despite the negative factors, the MRI gives a Medium Investment risk signal.

**Overall Recommendation:**

Based on this analysis, RXRX appears to be a speculative investment. While the hybrid signal provides a buying opportunity, this recommendation does not correspond with the rest of the negative indicators. Investors should consider the significant risks and potential for further losses, as well as potential upsides from future successful trials and breakthroughs. Proceed with caution and consider a small position size as part of a diversified portfolio.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.